VBI Vaccines IncOver The Counter Market:VBIVQ
- LAST PRICE0.0005
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots---/ ---
- Ask / Lots---/ ---
- Open / Previous Close--- / 0.0005
- Day Range---
- 52 Week Range
- Volume---
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | VBIVQ |
|---|---|---|
| 09:32 ET | 5307 | 0.0005 |
| 10:31 ET | 476 | 0.0005 |
| 11:09 ET | 101 | 0.0005 |
| 11:12 ET | 576 | 0.0005 |
| 11:14 ET | 1370 | 0.0005 |
| 12:24 ET | 828 | 0.0005 |
| 12:28 ET | 1761 | 0.0005 |
| 02:56 ET | 2000 | 0.0005 |
| 02:57 ET | 133 | 0.0005 |
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
VBI Vaccines Inc | 14.3K | 0.0x | --- |
Rosetta Genomics Ltd | 590.0 | 0.0x | --- |
International Stem Cell Corp | 481.1K | -0.9x | --- |
Fresh Tracks Therapeutics Inc | 4.4M | -0.5x | --- |
Correlate Energy Corp | 4.0M | -0.1x | --- |
BioNexus Gene Lab Corp | 5.9M | -3.0x | --- |
Company Information
VBI Vaccines Inc. is a commercial-stage biopharmaceutical company. Through its approach to virus-like particles (VLPs), including an enveloped VLP (eVLP) platform technology and a proprietary mRNA-launched eVLP (MLE) platform technology, the Company develops vaccine candidates that mimic the natural presentation of viruses, designed to elicit the innate power of the human immune system. The Company is focused on targeting and overcoming significant infectious diseases, including hepatitis B (HBV), coronaviruses, and cytomegalovirus (CMV), as well as aggressive cancers including glioblastoma (GBM). Its product pipeline includes an approved vaccine and multiple late- and early-stage investigational programs. PreHevbrio is its approved vaccine for hepatitis B. Its Prophylactic Candidates for coronavirus disease include VBI-2901, VBI-2905, VBI-2902, and others. VBI-1501 is its Prophylactic Candidate for cytomegalovirus. VBI-2601 and VBI-1901 are the therapeutic candidates for HBV and GBM.
Contact Information
- Headquarters
- 160 Second Street, CambridgeCAMBRIDGE, MA, United States 02142
- Phone
- 617-830-3031
- Fax
- ---
Executives
- Independent Chairman of the Board
- Steven Gillis
- President, Chief Executive Officer, Director
- Jeffrey Baxter
- Chief Financial Officer, Director, Head of Corporate Development
- Nell Beattie
- Chief Scientific Officer
- David Anderson
- Global Head of Manufacturing and SciVac General Manager
- Avi Mazaltov
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $14.3K |
|---|---|
Revenue (TTM) | $9.4M |
Shares Outstanding | 28.7M |
VBI Vaccines Inc does not pay a dividend. | |
Beta | 2.14 |
EPS | $-6.93 |
Book Value | $0.31 |
P/E Ratio | 0.0x |
Price/Sales (TTM) | 0.0 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -766.73% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
